Endonovo Therapeutics, Inc. Share Price Other OTC
Equities
ENDV
US29272H3003
Biotechnology & Medical Research
Sales 2021 | 0.07 5.83 | Sales 2022 | 0.14 10.79 | Capitalization | 3.5M 279M |
---|---|---|---|---|---|
Net income 2021 | -3M -239M | Net income 2022 | -18M -1.43B | EV / Sales 2021 | 112,421,804 x |
Net Debt 2021 | 7.1M 566M | Net Debt 2022 | 7.15M 570M | EV / Sales 2022 | 78,689,579 x |
P/E ratio 2021 |
-0.3
x | P/E ratio 2022 |
-0.14
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.47% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 29/02/12 |
Don Calabria
COO | Chief Operating Officer | 53 | - |
Steven Barnes
IRC | Investor Relations Contact | - | 30/04/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 29/02/12 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |